(Reuters) -Tylenol-maker Kenvue stock rose in European trading on Tuesday, even after U.S. President Donald Trump linked its popular pain medication to autism risk during pregnancy.
Kenvue’s Frankfurt-listed shares gained 6%, rebounding from a record low hit the previous day ahead of Trump’s extraordinary White House press conference.
Citi analysts said they expected the stock to recover, citing the absence of new scientific evidence.
“Overall, we see limited judicial risk following today’s announcement, but there could be some impact on Tylenol consumption due to negative headlines,” they wrote.
Many doctors reject the claim, and Kenvue reiterated there is no scientific link between acetaminophen, the active ingredient in Tylenol, and autism, warning that such suggestions could endanger maternal health.
The Food and Drug Administration said it will update labels on Tylenol and generic versions to reflect evidence of a possible link between acetaminophen use during pregnancy and neurological conditions such as autism and ADHD, but stressed that no causal relationship has been established.
Kenvue shares in Frankfurt are down 22.6% year-to-date.
(Reporting by Danilo Masoni; Editing by Amanda Cooper)
Brought to you by www.srnnews.com
